HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ: LRMR ) with a Buy rating and announces Price Target of $10.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.